Fig. 6.

Kaplan–Meier estimates of cumulative PFS (upper raw) and OS (lower raw) in the subgroups treated with nivolumab and ipilimumab (n = 15). In each subgroup, patients were stratified by plasma levels of MMP1, IL-1β, sTNFR-1, and IL-6. The cut-off values between the high and low groups were the median values. p values (log-rank test) are shown